has renewed and expanded its network contract with
Orange Business Services
to include an end-to-end
unified communications and collaboration
solution to connect more than 11,000 staff around the world.
Lonza, a leading supplier to the pharmaceutical, healthcare and life science industry, has been an Orange Business Services customer for more than a decade. After a competitive bidding process, Lonza awarded Orange Business Services the contract for four additional years.
The Orange Business Services network solution connects more than 60 sites in 17 countries to the IP VPN, using Ethernet links for the major locations and DSL access for small and medium locations. The
can carry real-time Telepresence, video and voice traffic ensuring best-in-class user experience.
Ernst Hutter, head of Global IT-Infrastructure Services, Lonza AG, said: “Orange Business Services is providing us a solution that is risk-free in terms of business continuity, allowing us to react quickly to business needs. It is flexible and can easily increase bandwidth, connect locations and support new applications and collaboration needs. Additionally, we are very satisfied with the network services stability and performance. The unified communications and collaboration aspect of the new contract enables efficient collaboration between geographically-dispersed experts, which is particularly important to Lonza.”
“This contract renewal and expansion represents the continued trust Lonza has in Orange Business Services,” said Dr. Helmut Reisinger, senior vice president for Europe, Russia and CIS, Orange Business Services. “Orange Business Services offers the fit for purpose service at each location to support Lonza’s business requirements for a robust, end-to-end unified communications and collaboration solution. Our high-bandwidth, high-quality and secure network is a key enabler for this global solution.”
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients.